Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Main billing specialty: obstetrics & gynecology.
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.30.8× | 25% | 7,960 in 2030+2.4%/yr |
| Florida | 83 | 6,350−1.1%/yr | −1.1%/yr | 3.11.1× | 27% | 7,730 in 2030+3.3%/yr |
| New York | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.71.3× | 30% | 6,960 in 2030+2.2%/yr |
| Texas | 48 | 4,624−1.2%/yr | −1.2%/yr | 2.40.8× | 16% | 5,220 in 2030+2.1%/yr |
| Pennsylvania | 52 | 4,366−2%/yr | −2%/yr | 3.51.3× | 10% | 4,620 in 2030+0.9%/yr |
| Illinois | 30 | 3,307−3.1%/yr | −3.1%/yr | 2.60.9× | 12% | 3,820 in 2030+2.4%/yr |
| Massachusetts | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.61.3× | 17% | 3,720 in 2030+2.6%/yr |
| Ohio | 26 | 3,124−0.8%/yr | −0.8%/yr | 3.11.1× | 7% | 3,530 in 2030+2%/yr |
| New Jersey | 25 | 2,622+0.6%/yr | +0.6%/yr | 2.71.0× | 20% | 3,090 in 2030+2.8%/yr |
| Michigan | 15 | 2,577−6%/yr | −6%/yr | 3.41.2× | 11% | 2,550 in 2030−0.1%/yr |
| Maryland | 37 | 2,575−1.2%/yr | −1.2%/yr | 3.11.1× | 16% | 2,650 in 2030+0.5%/yr |
| North Carolina | 30 | 2,572−2.1%/yr | −2.1%/yr | 2.91.0× | 10% | 2,740 in 2030+1.1%/yr |
| Virginia | 31 | 2,534−2.5%/yr | −2.5%/yr | 2.60.9× | 15% | 2,790 in 2030+1.6%/yr |
| Georgia | 18 | 2,052−1%/yr | −1%/yr | 2.60.9× | 8% | 2,340 in 2030+2.2%/yr |
| Indiana | 18 | 2,015−2.6%/yr | −2.6%/yr | 3.11.1× | 13% | 2,050 in 2030+0.2%/yr |
| Arizona | 21 | 1,973+0.3%/yr | +0.3%/yr | 2.91.0× | 22% | 2,360 in 2030+3%/yr |
| Tennessee | 25 | 1,879−1.2%/yr | −1.2%/yr | 2.91.0× | 11% | 1,860 in 2030−0.2%/yr |
| Washington | 21 | 1,715−1.7%/yr | −1.7%/yr | 2.40.9× | 4% | 2,300 in 2030+5%/yr |
| Missouri | 13 | 1,625−3.4%/yr | −3.4%/yr | 2.91.0× | 10% | 1,650 in 2030+0.2%/yr |
| Wisconsin | 12 | 1,602−0.7%/yr | −0.7%/yr | 3.11.1× | 7% | 1,910 in 2030+3%/yr |
| Minnesota | 18 | 1,547−1%/yr | −1%/yr | 3.81.4× | 9% | 2,280 in 2030+6.7%/yr |
| South Carolina | 15 | 1,394−1.5%/yr | −1.5%/yr | 2.20.8× | 7% | 1,670 in 2030+3.1%/yr |
| Colorado | 11 | 1,230+1.8%/yr | +1.8%/yr | 2.81.0× | 8% | 1,580 in 2030+4.2%/yr |
| Kentucky | 13 | 1,108−5.7%/yr | −5.7%/yr | 2.70.9× | 9% | 950 in 2030−2.6%/yr |
| Oklahoma | 7 | 1,055−0.1%/yr | −0.1%/yr | 2.30.8× | 0% | 1,240 in 2030+2.7%/yr |
| Oregon | 10 | 1,031+0.7%/yr | +0.7%/yr | 2.71.0× | 14% | 1,100 in 2030+1.1%/yr |
| Connecticut | 9 | 999−0.1%/yr | −0.1%/yr | 3.31.2× | 8% | 1,420 in 2030+6%/yr |
| Alabama | 8 | 942−6.1%/yr | −6.1%/yr | 2.40.9× | 13% | 900 in 2030−0.8%/yr |
| Iowa | 12 | 908−1.5%/yr | −1.5%/yr | 2.20.8× | 11% | 880 in 2030−0.4%/yr |
| Kansas | 14 | 868−1.5%/yr | −1.5%/yr | 2.30.8× | 11% | 890 in 2030+0.4%/yr |
| Arkansas | 6 | 815−2%/yr | −2%/yr | 2.30.8× | 14% | 780 in 2030−0.7%/yr |
| Louisiana | 4 | 800−6.4%/yr | −6.4%/yr | 2.20.8× | 14% | 710 in 2030−2%/yr |
| West Virginia | 4 | 616−2.8%/yr | −2.8%/yr | 3.21.2× | 5% | 580 in 2030−1.1%/yr |
| Mississippi | 8 | 600−6.8%/yr | −6.8%/yr | 1.70.6× | 9% | 590 in 2030−0.3%/yr |
| Nevada | 3 | 560−0.8%/yr | −0.8%/yr | 2.10.8× | 20% | 610 in 2030+1.5%/yr |
| New Hampshire | 3 | 531−0.4%/yr | −0.4%/yr | 2.50.9× | 6% | 910 in 2030+9.3%/yr |
| Nebraska | 4 | 529−3.8%/yr | −3.8%/yr | 2.20.8× | 9% | 650 in 2030+3.6%/yr |
| Idaho | 5 | 440+2.5%/yr | +2.5%/yr | 2.40.8× | 9% | 690 in 2030+7.8%/yr |
| New Mexico | 5 | 427−0.8%/yr | −0.8%/yr | 2.00.7× | 16% | 400 in 2030−1.2%/yr |
| Montana | 7 | 426+5.8%/yr | +5.8%/yr | 2.40.8× | 8% | 720 in 2030+9.1%/yr |
| Delaware | 8 | 418−3.4%/yr | −3.4%/yr | 2.60.9× | 13% | 530 in 2030+4.1%/yr |
| Utah | 2 | 384−2.1%/yr | −2.1%/yr | 1.90.7× | 11% | 380 in 2030−0.1%/yr |
| Rhode Island | 6 | 346−0.6%/yr | −0.6%/yr | 4.21.5× | 0% | 430 in 2030+3.6%/yr |
| South Dakota | 2 | 342−0.3%/yr | −0.3%/yr | 2.81.0× | 0% | 380 in 2030+1.9%/yr |
| District of Columbia | 4 | 307+6.1%/yr | +6.1%/yr | 5.21.9× | 31% | 460 in 2030+6.8%/yr |
| Maine | 3 | 290−6%/yr | −6%/yr | 2.00.7× | 7% | 370 in 2030+4%/yr |
| Alaska | 2 | 275+7.4%/yr | +7.4%/yr | 2.30.8× | 26% | 220 in 2030−3.5%/yr |
| North Dakota | 1 | 216−1.3%/yr | −1.3%/yr | 2.30.8× | 10% | 220 in 2030+0.5%/yr |
| Hawaii | 2 | 214+5.1%/yr | +5.1%/yr | 1.90.7× | 14% | 220 in 2030+0.1%/yr |
| Vermont | 4 | 193−5.7%/yr | −5.7%/yr | 1.80.6× | 9% | 360 in 2030+11%/yr |
| Wyoming | 0 | 120+2.1%/yr | +2.1%/yr | 1.10.4× | 20% | 140 in 2030+2.6%/yr |
Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 169 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 31 companies. The most active:
Product codes: HIH (hysteroscope (and accessories)), MNB (device, thermal ablation, endometrial). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 27% of the cases CMS names in California; 57 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Kidney stone management | 3,401 | 159,938−1.4%/yr | −1.4%/yr | 172,300 in 2030+1.2%/yr |
| BPH procedures | 2,196 | 155,142−6.4%/yr | −6.4%/yr | 148,000 in 2030−0.8%/yr |
| Incontinence, prolapse & sacral neuromodulation | 1,058 | 73,050−1.4%/yr | −1.4%/yr | 83,900 in 2030+2.3%/yr |
| Prostatectomy & nephrectomy | 592 | 37,032−1.1%/yr | −1.1%/yr | 45,600 in 2030+3.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 16 companies reported engagement with surgeons in the covered states worth $1.7M in consulting, speaking, meals and travel tied to these products, about $1,931 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.